(19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 14 October 2004 (14.10.2004)

PCT

(10) International Publication Number WO 2004/087070 A3

(51) International Patent Classification⁷: A01N 61/00. C12Q 1/00, G01N 33/566, 33/573, 33/574

(21) International Application Number:

PCT/US2004/009574

- (22) International Filing Date: 26 March 2004 (26.03.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/458,090

27 March 2003 (27.03.2003) US

- (71) Applicant (for all designated States except US): PTC THERAPEUTICS, INC. [US/US]; 100 Corporate Court, Middlesex Business Center, South Plainfield, NJ 07080 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): TROTTA, Christopher, R. [US/US]; 198 Scobee Lane, Somerset, NJ 08873 (US).
- (74) Agents: CORUZZI, Laura, A. et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 4 August 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF IDENTIFYING COMPOUNDS THAT TARGET tRNA SPLICING ENDONUCLEASE AND USES OF SAID COMPOUNDS AS ANTI-FUNGAL AGENTS

(57) Abstract: The present invention relates to a method for screening and identifying compounds that modulate the activity of a fungal tRNA splicing endonuclease. In particular, the invention provides assays for the identification of compounds that inhibit or reduce the activity of a fungal tRNA splicing endonuclease. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for preventing, treating, managing and/or ameliorating a fungal infection or fungal infestation or one or more symptoms thereof.



INTERNATIONAL SEARCH REPORT

International application No.

		F	PCT/US04/09574	<u>; </u>			
	A. CLASSIFICATION OF SUBJECT MATTER						
IPC(7) : A01N 61/00; C12Q 1/00; G01N 33/566, 573 AND 574 US CL : 435/4, 6, 7.2, 7.21, 41, 69.2, 91.3, 183; 514/1, 2							
According to International Patent Classification (IPC) or to both national classification and IPC							
B. FIELDS SEARCHED							
Minimum d	Minimum documentation searched (classification system followed by classification symbols)						
U.S. : 4	135/4, 6, 7.2, 7.21, 41, 69.2, 91.3, 183; 514/1, 2	or of Grassinourion symbols,	,				
Documentat	tion searched other than minimum documentation to	the endough the second of the					
	to i post of the contract of t	me extent that such docume	nts are included	in the fields searched			
		·					
Blectronic d	ata base consulted during the international search (na Continuation Sheet	ame of data base and, where	e practicable, sea	rch terms used)			
Tibaso 366 C	Continuation Sheet						
	TUMENTS CONSIDERED TO BE RELEVANT						
Category *	Citation of document, with indication, where	appropriate, of the relevant	t passages	Relevant to claim No.			
X	US 5,726,195 A (HILL et al.) 10 March 1998, see	entire patent.		29-32, 40, 41			
x	WO 01/25486 A1 (RANA) 12 April 2001, see enti	re document, especially the	shatmat	20 22 40 44			
	examples and claims.	are decembers, especially me	austract,	29-32, 40, 41			
Y				1-28, 33-39			
x	WO 02/092927 A1 (A1 MOTTINE) 24 C			·			
,	WO 02/083837 A1 (ALMSTRAD) 24 October 200 abstract, examples and claims.	2, see entire document, esp	ecially the	29-32, 40, 41			
Y	i i i i i i i i i i i i i i i i i i i			1-28, 33-39			
				1-20, 55-59			
X	WO 02/083953 A1 (RANDO et al.) 24 October 20	02, see entire document, esp	pecially the	29-32, 40, 41			
Y	abstract, examples and claims.						
•			1	1-28, 33-39			
Y	VAUGHAN, M.D. et al. Methionine In and Out of	Proteins: Targets for Drug	Design	1-41			
	Current Medicinal Chemistry, 2002, Vol. 9, No. 3, p.		rticle.	1-41			
			i				
			ľ				
Further	documents are listed in the continuation of Box C.	See patent fam	ilu annev				
	pecial categories of cited documents:		=	tional filing date or priority date			
	defining the general state of the art which is not considered to be of	and not in conflict	with the application bu	t cited to understand the			
particular i	relevance		underlying the invention	en.			
"E" earlier app	lication or patent published on or after the international filing date	"X" document of partic	ular relevance; the clair	med invention cannot be to involve an inventive step			
	which may throw doubts on priority claim(s) or which is cited to	when the documen	t is taken alone	to myorve an myendye steb			
establish th	he publication date of another citation or other special reason (as	"Y" document of partice	lar relevance; the clair	ned invention cannot be			
specified)				hen the document is combined uch combination being obvious			
"O" document	referring to an oral disclosure, use, exhibition or other means	to a person skilled i		variablization benig 00 vious			
"P" document a	published prior to the international filing date but later than the	"&" document member	of the same patent fam	ily			
priority date claimed							
Date of the ac	Date of the actual completion of the international search Date of mailing of the international search report			report			
04 April 2005 (04.04.2005) 0 9 JUN 2005							
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents Authorized officer Mark L. Shibuya Bell-Hown for				2.44.0			
	Stop PCT, Attn: ISA/US missioner for Patents	Mark L. Shibulal	Sell-170	1 stronger			
P.O. Box 1450							
Alexandria, Virginia 22313-1450 Telephone No. (571) 272-1600 acsimile No. (703) 305-3230							
PCTGS ACIO (constallation)							

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/09574

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

ategory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim N
Y	WANG, M.J. et al. Substrate Masking: Binding of RNA by EGTA-Inactivated Micrococcal Nuclease Results in Artifactual Inhibition of RNA Processing Reactions. Nucleic Acids Research, 1990, Vol. 18, No. 22, pages 6625-6631, see entire publication, especially the abstract, pages 6625-6626, bridging paragraph, page 6626, paragraph, 6, page 6627, paragraph 8.	1-41
Y	LI, H. et al. Crystal Structure and Evolution of a Transfer RNA Splicing Enzyme. Science, April 1998, Vol. 280, No. 10, pages 279-284, see entire article.	1-41
Y	HYDE-DERUYSCHER, R. et al. Detection of Small-Molecule Enzyme Inhibitors with Peptides Isolated from Phage-Displayed Combinatorial Peptide Libraries. Chemistry & Biology, 2000, Vol. 7, pages 17-25, see entire article, especially the abstract, Table I and pages 23-24.	1-41
Y	ABELSON, J. et al. tRNA Splicing. Journal of Biological Chemistry, May 1998, Vol. 273, No. 21, pages 12685-12688, see entire article.	1-41
Y	TROTTA, C.R. et al. The Yeast tRNA Splicing Endonuclease: A Tetrameric Enzyme with Two Active Site Subunits Homologous to the Archaeal tRNA Endonuclease. Cell, June 1997, Vol. 89, pages 849-858, see entire article.	1-41
	•	
		-
}		
	}	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/09574

	No. II	
This in	nternati	tional search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.		Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. [Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. [コ —	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box N	ío. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This In	ternatio See Co	ional Searching Authority found multiple inventions in this international application, as follows: ontinuation Sheet
1. [2.] 3. [As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. Remark	r	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

•	International application No.
INTERNATIONAL SEARCH REPORT	PCT/US04/09574
	<u> </u>
·	
	•
BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKI	NG
This application contains the following inventions or groups of inventions which are	e not so linked as to form a single general inventive
concept under PCT Rule 13.1. In order for all inventions to be examined, the appro	priate additional examination fees must be paid.
Group I, claim(s) 1-28 and 33-39, drawn to methods for identifying a compound tha	it modulates fimoal tRNA splicing endonuclease
activity.	a manager and at aprioting official consequences
Group II, claim(s) 29-32, 40 and 41, drawn to methods of preventing, treating, many	aging or ameliorating a fungal infection by
administering an antiproliferative compound identified by the Group I method.	
The inventions listed as Groups I and II do not relate to a single general inventive co	oncent under PCT Pule 12 1 hecouse, under PCT Pul
13.2, they lack the same or corresponding special technical features for the followin	g reasons: the methods of Groups I and II are
distinctly different methods drawn to different method objectives. The antifungal co	ompounds of Group II and derived from the Group I
methods do not represent a "special" technical feature because antifungal compound	is are known in the art. See e.g., WO 02/083953A1;
WO 02/083837A1; and WO 01/25486A1.	
Continuation of B. FIELDS SEARCHED Item 3:	
WEST: PGPB, USPT, USOC, EPAB, JPAB, DWPL, TDBD.	
STN: CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS	